Fusen Pharmaceutical Company Limited (1652.HK)
HKD 0.26
(4.0%)
HKD 0.26
(4.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 279.49 Million CNY | 45.62% |
| 2022 | 186.41 Million CNY | 27.12% |
| 2021 | 146.64 Million CNY | -19.35% |
| 2020 | 181.83 Million CNY | 9.47% |
| 2019 | 166.1 Million CNY | 30.07% |
| 2018 | 127.7 Million CNY | -2.12% |
| 2017 | 130.47 Million CNY | 22.94% |
| 2016 | 106.13 Million CNY | 20.09% |
| 2015 | 88.37 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 71.2 Million CNY | 0.0% |
| 2024 Q1 | 71.2 Million CNY | 2.33% |
| 2023 Q1 | 75.84 Million CNY | -7.41% |
| 2023 Q4 | 69.58 Million CNY | -15.71% |
| 2023 FY | 271.45 Million CNY | 45.62% |
| 2023 Q2 | 75.84 Million CNY | 0.0% |
| 2023 Q3 | 82.55 Million CNY | 8.85% |
| 2022 Q1 | 40.89 Million CNY | -30.64% |
| 2022 FY | 186.41 Million CNY | 27.12% |
| 2022 Q3 | 81.91 Million CNY | 100.32% |
| 2022 Q2 | 40.89 Million CNY | 0.0% |
| 2022 Q4 | 81.91 Million CNY | 0.0% |
| 2021 Q2 | 31.87 Million CNY | 0.0% |
| 2021 Q3 | 58.95 Million CNY | 84.98% |
| 2021 FY | 146.64 Million CNY | -19.35% |
| 2021 Q4 | 58.95 Million CNY | 0.0% |
| 2021 Q1 | 31.87 Million CNY | -31.33% |
| 2020 Q4 | 46.41 Million CNY | 0.0% |
| 2020 Q2 | 43.41 Million CNY | 0.0% |
| 2020 FY | 181.83 Million CNY | 9.47% |
| 2020 Q1 | 43.41 Million CNY | 29.61% |
| 2020 Q3 | 46.41 Million CNY | 6.9% |
| 2019 FY | 166.1 Million CNY | 30.07% |
| 2019 Q4 | 33.49 Million CNY | 0.0% |
| 2019 Q3 | 33.49 Million CNY | -12.02% |
| 2019 Q2 | 38.07 Million CNY | 0.0% |
| 2019 Q1 | 38.07 Million CNY | 86.75% |
| 2018 Q3 | 20.38 Million CNY | -44.55% |
| 2018 Q4 | 20.38 Million CNY | 0.0% |
| 2018 Q1 | 36.76 Million CNY | -14.82% |
| 2018 Q2 | 36.76 Million CNY | 0.0% |
| 2018 FY | 127.7 Million CNY | -2.12% |
| 2017 Q1 | 30.97 Million CNY | -12.13% |
| 2017 FY | 130.47 Million CNY | 22.94% |
| 2017 Q4 | 43.16 Million CNY | 0.0% |
| 2017 Q2 | 30.97 Million CNY | 0.0% |
| 2016 Q1 | 26.08 Million CNY | 0.0% |
| 2016 Q4 | 35.25 Million CNY | 0.0% |
| 2016 FY | 106.13 Million CNY | 20.09% |
| 2016 Q2 | 26.08 Million CNY | 0.0% |
| 2015 FY | 88.37 Million CNY | 0.0% |
| 2015 Q3 | 21.75 Million CNY | 0.0% |
| 2015 Q4 | 26.08 Million CNY | 19.87% |
| 2015 Q2 | 21.75 Million CNY | 0.0% |
| 2015 Q1 | 21.75 Million CNY | 0.0% |
| 2014 Q4 | 21.75 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 24.42 Million HKD | -1044.325% |
| Grand Pharmaceutical Group Limited | 3.86 Billion HKD | 92.761% |
| Extrawell Pharmaceutical Holdings Limited | 35.52 Million HKD | -686.697% |
| Wai Yuen Tong Medicine Holdings Limited | 353.93 Million HKD | 21.033% |
| Qianhai Health Holdings Limited | 17.1 Million HKD | -1534.253% |
| Lee's Pharmaceutical Holdings Limited | 590.99 Million HKD | 52.708% |
| Essex Bio-Technology Limited | 1.22 Billion HKD | 77.258% |
| Tongfang Kontafarma Holdings Limited | 503.46 Million HKD | 44.486% |
| PuraPharm Corporation Limited | 216.62 Million HKD | -29.018% |
| SSY Group Limited | 1.98 Billion HKD | 85.89% |
| JBM (Healthcare) Limited | 163.87 Million HKD | -70.55% |
| Jacobson Pharma Corporation Limited | 287.34 Million HKD | 2.735% |
| China Resources Pharmaceutical Group Limited | 29.35 Billion HKD | 99.048% |